Gupta, Shilpa

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 1,477

Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology

Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H. H., Cho, S. Y., D’Amico, A. V., et al. (2025) · Journal of the National Comprehensive Cancer Network

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 146

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 144

Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

Jimeno, A., Gupta, S., Sullivan, R., Do, K. T., Akerley, W. L., Wang, D., Teoh, D., Schalper, K., Zacharek, S. J., Sun, J., et al. (2020) · Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 41